A multicenter open label phase II study of to assess the efficacy and safety of APO866 [daporinad] in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma.

Trial Profile

A multicenter open label phase II study of to assess the efficacy and safety of APO866 [daporinad] in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2016

At a glance

  • Drugs Daporinad (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Therapeutic Use
  • Sponsors TopoTarget
  • Most Recent Events

    • 23 Mar 2016 Results published in the JAMA Dermatology
    • 02 Jun 2015 According to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology, due to lack of efficacy study was stopped after enrolment of 14 patients.
    • 02 Jun 2015 Primary endpoint has not been met. (The proportion of eligible patients with refractory or relapsed CTCL whom have a complete response or partial response on cutaneous lesions (Tumor Burden Index) and extra-cutaneous disease.), according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top